Review on: Formulation and evaluation of transdermal patches of prednisolone for treatment of skin inflammation

Transdermal drug delivery systems (TDDS) have become a promising alternative to traditional oral administration for managing inflammatory disorders. They provide controlled drug release, better bioavailability, and fewer systemic side effects. Prednisolone, a strong glucocorticoid used for conditions like rheumatoid arthritis, psoriasis, and allergic inflammation, faces problems with first-pass metabolism and gastrointestinal irritation when taken orally. Transdermal patches of prednisolone tackle these issues by allowing sustained release and targeted delivery through the skin. This could improve treatment results. This review looks closely at the formulation strategies, evaluation methods, and therapeutic effectiveness of prednisolone-loaded transdermal patches for treating inflammation. Key formulation approaches, including matrix, reservoir, and drug-in-adhesive systems, are examined along with important excipients such as hydroxypropyl methylcellulose, penetration enhancers like ethanol and oleic acid, and plasticizers. We discuss evaluation parameters such as drug release kinetics, skin permeation using Franz diffusion cells, and stability under ICH guidelines.